Home › Trials › NCT05786131

Comparing complete revascularization to culprit lesion only PCI in NSTEMI patients

Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI (-COMPLETE-NSTEMI-)

Not applicable Interventional Leipzig Heart Science gGmbH · NCT05786131

This study tests if treating all blocked arteries instead of just the main problem artery helps people with NSTEMI feel better and recover faster.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment3390 (estimated)
Ages18 Years and up
SexAll
SponsorLeipzig Heart Science gGmbH Academic / other
Locations58 sites (Graz and 57 other locations)
Trial IDNCT05786131 on ClinicalTrials.gov

What this trial studies

This trial investigates whether performing multivessel percutaneous coronary intervention (PCI) is more effective than treating only the identified culprit lesion in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease. It is a prospective, randomized, controlled, multicenter, open-label trial that aims to provide insights into the benefits of complete revascularization. Participants will be randomly assigned to receive either complete revascularization or culprit-lesion only PCI. The study will assess outcomes related to heart health and recovery.

Who should consider this trial

Good fit: Ideal candidates for this study are adults diagnosed with NSTEMI and multivessel coronary artery disease who have an identifiable culprit lesion.

Not a fit: Patients who may not benefit include those with severe comorbidities, prior coronary artery bypass grafts, or contraindications for coronary revascularization.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies for NSTEMI patients, potentially enhancing recovery and reducing future cardiac events.

How similar studies have performed: Other studies have explored similar approaches, but this trial aims to provide more definitive evidence regarding the superiority of complete revascularization in this specific patient population.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* NSTEMI as suggested by high-sensitivity troponin algorithms
* Multivessel coronary artery disease
* Identifiable culprit lesion
* Informed consent

Exclusion Criteria:

* Age \<18 years
* Cardiogenic shock
* Sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)
* Contraindication for coronary revascularization
* Prior coronary artery bypass graft
* Indication for coronary artery bypass graft surgery
* Non-culprit lesion located in the left main coronary artery
* Co-morbidity with life expectancy less than 6 months
* Type 2 myocardial infarction
* Pregnancy and breast feeding period

Where this trial is running

Graz and 57 other locations

+8 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Non-ST-elevation Myocardial InfarctionMultivessel Coronary Artery DiseaseNSTEMIMultivessel coronary artery diseaseculprit-lesion only PCImultivessel percutaneous coronary intervention
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.